Clinical Trials Logo

Plasmodium Falciparum clinical trials

View clinical trials related to Plasmodium Falciparum.

Filter by:

NCT ID: NCT06300970 Completed - Malaria Clinical Trials

Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia

Start date: August 9, 2022
Phase: Phase 4
Study type: Interventional

To assess the efficacy of both first-line antimalarial medications used for the treatment of uncomplicated Plasmodium falciparum malaria infections in two geographic regions in Liberia.

NCT ID: NCT05400746 Recruiting - Malaria Clinical Trials

A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK

Start date: November 2, 2022
Phase: Early Phase 1
Study type: Interventional

This is an open label, single-site, first-in-human, dose-escalation Phase Ia study to assess safety and immunogenicity of the Plasmodium falciparum malaria vaccine candidate Pfs48/45 in Matrix-M adjuvant in healthy adults living in the UK

NCT ID: NCT04788862 Completed - Malaria Clinical Trials

A Study of Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection in Tanzania

Start date: July 18, 2022
Phase: N/A
Study type: Interventional

This will be a single-centre, open label trial to determine the safety and feasibility of CHMI model using Plasmodium falciparum-infected cryopreserved erythrocytes administered to healthy Tanzanian adults with varying prior exposure to P. falciparum.

NCT ID: NCT04661579 Completed - Clinical trials for Plasmodium Falciparum

RTS,S/AS01E Hypo-immuno-responsiveness Study

Start date: November 6, 2020
Phase: Phase 2
Study type: Interventional

The proposed trial design has been developed to answer several questions related to the nature of RTS,S vaccine efficacy in African adults that may be influenced by concurrent and/or past P. falciparum infection leading to a state of immunologic hypo-responsiveness. The proposed study design encompasses five groups. Three groups (Groups 1, 2, and 3) will be administered RTS,S/AS01E on a 0, 1, 7 month schedule with Dose 3 delivered as a 1/5th fractional dose. Two groups (Groups 4 and 5) will be administered a comparator vaccine on a 0, 1, 7 month schedule.

NCT ID: NCT04445103 Terminated - Clinical trials for Cardiovascular Diseases

The Malaria Heart Disease Study

Start date: June 21, 2020
Phase:
Study type: Observational

The Malaria Heart Disease Study is a prospective longitudinal cohort study of a random sample of approximately 1200 individuals from the state of Acre in Brazil. The overall hypothesis is that patients who have (i) previously suffered from a malaria infection or (ii) patients with ongoing symptomatic malaria will benefit from having an echocardiogram and blood tests performed as a screening tool to diagnose early cardiac impairment and prevent future cardiovascular disease.

NCT ID: NCT04203186 Withdrawn - Clinical trials for Plasmodium Falciparum

A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI)

ECG-CHMI
Start date: March 2020
Phase: N/A
Study type: Interventional

A comparison of Malaria events (symptoms and signs of malaria) experienced by subjects infected with PfSPZ Challenge (NF54) vs. PfSPZ Challenge (7G8).

NCT ID: NCT03452475 Completed - Clinical trials for Plasmodium Falciparum

Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children

TACTKenya
Start date: March 7, 2018
Phase: Phase 3
Study type: Interventional

This open-label randomised controlled clinical trial will compare the safety, tolerability, therapeutic efficacy and pharmacokinetics and pharmacodynamics of arterolane-piperaquine, arterolane-piperaquine plus mefloquine versus artemether-lumefantrine.in children with uncomplicated falciparum malaria in Kilifi, Kenya. This study will also provide an up to date insight on the current presence of antimalarial resistance in this site. In addition, all children will be treated with a single low dose of primaquine, dosing is age based. The investigators will recruit 219 patients aged 2 years to 12 years with acute uncomplicated falciparum malaria in Kilifi County Hospital.

NCT ID: NCT03219281 Not yet recruiting - Clinical trials for Plasmodium Falciparum

Prevalence Survey of Antimalarial Drug Resistance Markers at Sites in India

Start date: July 2017
Phase: N/A
Study type: Observational

This is a cross-sectional, observational study using dried blood samples collected from P. falciparum-infected individuals at the time of malaria diagnosis to measure the prevalence of known and candidate molecular markers of resistance to artemisinin and non-artemisinin ACT partner drugs. A maximum of 200 participants will be enrolled at each participating sites per year. Study duration is 1 years. Therefore total participant is up to 400. Prospective participants will have blood collected for dried blood spot (DBS) study sample after providing informed consent. Individuals with confirmed P. falciparum infection will have DBS samples included for molecular analyses for known and candidate molecular markers of antimalarial drug resistance.

NCT ID: NCT03172221 Completed - Diagnoses Disease Clinical Trials

Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women

HSRDT MiP
Start date: July 25, 2017
Phase:
Study type: Observational

This is a cross-sectional and multicentre clinical trial to study the performance of the Histidine Rich Protein 2 (HRP2) highly sensitive rapid diagnostic test (HS-RDT) for the detection of malaria during pregnancy in low transmission settings from Colombia and Indonesia. The new HS-RDT will be compared with conventional good quality RDTs, microscopy, and NAATs [loop-mediated isothermal amplification (LAMP), nested PCR (nPCR)], in peripheral blood samples with quantitative reverse transcription PCR (qRT-PCR) as reference standard.

NCT ID: NCT03138096 Completed - Malaria,Falciparum Clinical Trials

Safety and Protective Efficacy of Pb(PfCS@UIS4)

PbVac
Start date: May 29, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

In the underlying study, a genetically modified P. berghei parasite is used. P. berghei is one of the four Plasmodium species that causes malaria in rodents. The hypothesis is that immunization of humans with P. berghei will induce a cross-species immune response without the risk of a breakthrough infection. To further increase the potential for protective efficacy, the P. falciparum circumsporozoite (CS)- protein gene has been integrated in the P. berghei parasite, generating a genetically modified P. berghei parasite, abbreviated as Pb(PfCS@UIS4).